33.20Open33.20Pre Close0 Volume3 Open Interest220.00Strike Price0.00Turnover38.25%IV-0.21%PremiumDec 20, 2024Expiry Date33.74Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9444Delta0.0047Gamma7.27Leverage Ratio-0.0842Theta0.1236Rho6.87Eff Leverage0.0699Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet